

## Anti-Human HLA-DR Antibody

|                           |                                                         |
|---------------------------|---------------------------------------------------------|
| <b>Catalog Number:</b>    | 102701, 102702                                          |
| <b>Size:</b>              | 100 ug, 500 ug                                          |
| <b>Target Name:</b>       | HLA-DR, Major Histocompatibility Class II, MHC class II |
| <b>Regulatory Status:</b> | RUO                                                     |

### PRODUCT DETAILS

---

|                               |                                                                                                                                                                                                                                   |
|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Clone:</b>                 | L243                                                                                                                                                                                                                              |
| <b>Application:</b>           | Flow Cytometry                                                                                                                                                                                                                    |
| <b>Reactivity:</b>            | Human, Chimpanzee, Cynomolgus, Rhesus, Pig-tailed macaque, Baboon, African Green, Marmoset                                                                                                                                        |
| <b>Format:</b>                | Purified                                                                                                                                                                                                                          |
| <b>Isotype:</b>               | Mouse IgG2a                                                                                                                                                                                                                       |
| <b>Antibody Type:</b>         | Monoclonal                                                                                                                                                                                                                        |
| <b>Formulation:</b>           | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide                                                                                                                                                                |
| <b>Protein Concentration:</b> | 0.5 mg/mL                                                                                                                                                                                                                         |
| <b>Storage and Handling:</b>  | The antibody solution should be stored between 2°C and 8°C                                                                                                                                                                        |
| <b>Recommended Usage:</b>     | For flow cytometric staining, it is recommended to use less than 0.5 µg of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application |
| <b>Isotype Control:</b>       | 301501                                                                                                                                                                                                                            |
| <b>RRID:</b>                  | AB_3738647                                                                                                                                                                                                                        |

### BACKGROUND INFORMATION

---

HLA-DR is a major histocompatibility complex (MHC) class II molecule that plays a central role in adaptive immune responses by presenting antigenic peptides to CD4<sup>+</sup> T helper cells. It is primarily expressed on professional antigen-presenting cells (APCs), including dendritic cells, macrophages, B cells, and thymic epithelial cells, and its expression can be induced on other cell types under inflammatory conditions, particularly by interferon- $\gamma$ .

Structurally, HLA-DR is a heterodimer composed of an  $\alpha$  chain (DRA) and a  $\beta$  chain (DRB), each containing two extracellular domains, a transmembrane region, and a short cytoplasmic tail. The  $\alpha 1$  and  $\beta 1$  domains together form the peptide-binding groove, which accommodates peptides typically 13–25 amino acids in length. This groove is open at both ends, allowing for flexibility in peptide size. HLA-DR is highly polymorphic, particularly in the DRB genes, enabling the immune system to present a broad repertoire of antigenic peptides derived from pathogens or self-proteins. The ligands of HLA-DR are processed peptide antigens generated from extracellular or vesicular proteins that are internalized, degraded in endosomal compartments, and loaded onto HLA-DR molecules. Peptide loading is tightly regulated by accessory molecules, including the invariant chain (Ii), which prevents


premature peptide binding, and HLA-DM, which facilitates peptide exchange and stabilizes high-affinity peptide-HLA-DR complexes. The primary functional interaction of HLA-DR is with the T cell receptor (TCR) on CD4<sup>+</sup> T cells, initiating T cell activation and differentiation.

HLA-DR is strongly implicated in disease. Specific HLA-DR alleles are associated with susceptibility or protection in numerous autoimmune diseases, including rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus, and multiple sclerosis, reflecting differences in self-antigen presentation. Aberrant or reduced HLA-DR expression is also observed in cancer and sepsis, where impaired antigen presentation contributes to immune evasion or immunosuppression. Conversely, elevated HLA-DR expression on monocytes is often used as a marker of immune activation and immune competence.

Therapeutically, HLA-DR has both direct and indirect relevance. Anti-HLA-DR monoclonal antibodies have been explored in transplantation and hematologic malignancies to modulate immune responses or deplete malignant APCs. In cancer immunotherapy and vaccine development, effective antigen presentation via HLA-DR is essential for robust CD4<sup>+</sup> T cell help, supporting durable antitumor and antiviral immunity. Additionally, HLA-DR expression is widely used as a diagnostic and prognostic biomarker in immunology, oncology, and critical care settings.

## PRODUCT DATA

---



Human peripheral blood lymphocytes stained either with purified Anti-Human HLA-DR clone L243 (green histogram) or an isotype control (gray histogram), followed by PE anti-mouse IgG 2nd antibody.

This product is supplied subject to the terms and conditions at [www.innocyto.com/web/terms.php](http://www.innocyto.com/web/terms.php) and may only be used as provided in the stated terms. Products are for Research Use Only.